Shanghai Pharmaceuticals approves key resolutions at AGM

Shanghai Pharmaceuticals (SSE:601607) announced the resolutions passed at its 2024 Annual General Meeting of Shareholders. Key approvals included the 2024 annual report, board and supervisory board work reports, and the 2024 financial statements along with the 2025 financial budget. Shareholders also approved the 2024 profit distribution plan. Significantly, the meeting saw the approval of resolutions related to debt financing, including the issuance of debt financing products with specific terms regarding interest rates, maturity, and underwriting. The company's general authorization was also approved. The meeting was held in Shanghai and attended by 605 shareholders and proxies, representing 64.5943% of the company's total voting shares. Legal counsel confirmed the legitimacy and effectiveness of the meeting's procedures and resolutions.